Generic Diovan Availability
DIOVAN (valsartan - tablet;oral)
Approval date: July 18, 2001
Strength(s): 80MG, 160MG, 320MG [RLD]
Approval date: August 14, 2002
Has a generic version of Diovan been approved?
No. There is currently no therapeutically equivalent version of Diovan available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Diovan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Issued: March 21, 1995
Inventor(s): Buhlmayer; Peter & Ostermayer; Franz & Schmidlin; Tibur
Assignee(s): Ciba-Geigy Corp
Compounds of the formula ##STR1## in which R.sub.1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X.sub.1 is CO, SO.sub.2, or --O--C(.dbd.O)-- with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X.sub.2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R.sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O).sub.m --R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO.sub.n H.sub.2 where n is 2 or 3; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl, 5-tetrazolyl, SO.sub.3 H, PO.sub.2 H.sub.2, PO.sub.3 H.sub.2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.Patent expiration dates:
- September 21, 2012✓
- September 21, 2012
Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
Issued: October 26, 1999
Inventor(s): Pfeffer; Marc A. & Pfeffer; Janice M. & Braunwald; Eugene
Assignee(s): Brigham and Women's Hospital, Inc.
The invention involves a method for treating a human survivor of a heart attack and provides further improvement in survival following the heart attack by the early initiation and long-term administration of a renin-angiotensin system inhibitor, preferably an angiotensin converting enzyme inhibitor. The inhibitor may be used on its own, or in conjunction with other therapeutic compounds such as data blockers and thrombolytic agents. The preferred inhibitor is captopril.Patent expiration dates:
- October 26, 2016✓
- April 26, 2017✓
- October 26, 2016
Solid oral dosage forms of valsartan
Issued: September 25, 2001
Inventor(s): Wagner; Robert Frank & Katakuse; Yoshimitsu & Taike; Takashi & Yamato; Fujiki & Kohlmeyer; Manfred
Assignee(s): Novartis AG
The present invention is concerned with solid dosage forms comprising a) valsartan and optionally HCTZ, and b) pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.Patent expiration dates:
- June 18, 2017✓
- December 18, 2017✓
- June 18, 2017
- Diovan Consumer Information (Drugs.com)
- Diovan Consumer Information (Wolters Kluwer)
- Diovan Consumer Information (Cerner Multum)
- Diovan Advanced Consumer Information (Micromedex)
- Valsartan Consumer Information (Wolters Kluwer)
- Valsartan Consumer Information (Cerner Multum)
- Valsartan Advanced Consumer Information (Micromedex)
- Valsartan AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|